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Edited Transcript
This conversation was recorded on January 14, 2021
DR. RAMIREZ
(1) Today, I have the pleasure to have with me my
friend, Dr. Francesco Blasi, who will tell us about the
lessons that he learned concerning COVID in his city:
Milan, Italy. Then we will discuss, if there is time, a lit-
tle of how he sees COVID in 2021. To start, Francesco,
will you give us a brief overview of your position now
in Milan, and then can you start with your lessons
learned?
DR. BLASI
(2) Yes, thank you very much, Julio, is a pleasure to
to be here sharing with you the lessons we learned in
COVID-19. You know that Italy was the epicenter in
Europe; the disease started there, and then it spread
everywhere. I’m a professor of respiratory medicine
and part of the Department of Pathophysiology and
Transplantation at the University of Milan. In my hos-
pital, which is the main university hospital in Milan,
I’m head of the Internal Medicine Department and run
the Cardio-Respiratory Unit and Cystic Fibrosis at the
center here in Lombardy, the area around Milan. I work
mainly on respiratory infection, as I said, and my in-
terest moved from COPD to lung transplantation and
cystic fibrosis.
(3) The target of today is to give you some idea of what
happened in Italy, particularly in the area of Milan, dur-
ing the last year. One of our key tasks was to create
stability in a time of instability, which is on-going. In
dealing with this, I think evidence-based practice is key,
and we have seen how important clinical expertise is
when dealing with a new disease. On the other hand,
it is also important to consider what the patient wants.
Combining these factors, you will probably develop the
best practice for dealing with the disease.
(4) I think that the Coronavirus gives us a rocket stim-
ulus for health care management in our area. One
of the main problems in the management of COVID-
19 was and is how to deal with infection in the com-
munity. Clearly, the virus has been a strong stimulus
for technological innovation, considering, for example,
how fast the preparation of new vaccines has been. In
eight months, around five new vaccines have been de-
veloped for the disease. The other point is to determine
the best care to be applied to our patients in terms of
therapy.
(5) During the first two weeks of March last year,
we had a mortality of about 40% in my unit, and
then we started to change our therapeutic approach
to include steroids, anti-inflammatory drugs, and anti-
coagulation drugs, and the mortality rate dropped
down to 18%. I think it is important to evolve our med-
ical care for COVID—understanding the needs of our
patient, understanding what we’re doing and trying
to standardize our approach. We must improve and
evolve our approach, both our therapeutic approach
and also, in general terms, our management approach.
(6) Just to start, this is the first paper published by
our intensivists from Milan, looking into the first 1600
patients admitted to the ICU in Lombardy (Table 4—
Appendix).[1] It was immediately understood that the
mortality and severity of the disease is related to the
number and kind of comorbidities that the patient has,
as well as to their age. These are the two main points
that appear to be underlined by this paper, and I’ll
show you how this was confirmed by the other paper
we published.
(7) One of the main problems was that we started with
about 800 beds in the ICU in Lombardy, and by April,
we had more than 4,000 beds, but still this was not
enough to treat every patient that needed invasive ven-
tilation. So we tried to select as best we could which
patients should be in the ICU to give the best oppor-
tunity to our patients. Of course, it was very hard to
choose which patients should be intubated and which
should not.
(8) We changed our approach and management, start-
ing from the emergency room. We divided our emer-
gency room into 2 separate sections: one for patients
with suspected COVID, the other for patients with no
suspicion (Figure 1). We moved each patient through
one of the three columns—the green pathway, yel-
low/red pathway, and triage for non-COVID patients.
We divided the emergency room with dedicated radi-
ologists, one for suspected COVID and one for patients
with no suspected COVID. Then we went through the
pathway to possible discharge or moving the patient
to a general ward, high dependency unit, or ICU. This
was very important starting from the very early time in
COVID.
(9) The critical aspect of this was the education of our
personnel because we were not used to PPE (Table 1).
We began with lectures and live demonstrations, then
in-situ simulation, and then random calls to try to un-
derstand if the personnel were ready for these new ap-
proaches to the patient. And this involved not only the
ICU, but all the health care workers in our hospital. We
had over 3,800 personnel who took training, and we
endeavored to give them all the information that we
possibly could.
(10) Psychological support was also critical. It was im-
portant in the first wave, but even more so in the second
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Figure 1. Patient flow within the hospitals from presentation through assessment to final disposition. Green (minor), yellow (moderate) and red
(immediate) triage codes based on local emergency department triage protocol. CXR, chest X-ray; BA, bronchial aspirate; BAL, bronchoalveolar
lavage; CT, computed tomography; ICU, intensive care unit.[2]
L. Carenzo, E. Costantini, M. Greco, F. L. Barra, V. Rendiniello, M. Mainetti, R. Bui, A. Zanella, G. Grasselli, M. Logioia, A. Protti, M.
Cecconi, Aenesthesia, 75, 928–934 (2020) [journal on the Internet]. Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with
permission. © 2020 Association of Anaesthetists.
Table 1. COVID-19 healthcare workers training scheme.[2]
Training sessions Activities Duration Participant numbers Involved personnel
Lectures with live
demonstrations








In-situ simulation PPE donning 1 h 1–2 doctors





Isolated patient handling (low-resource prone
positioning)
Doffing of PPE
Random calls Surprise assessment with PPE checklists 20 min 1 person at a time
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wave because in the first wave, COVID-19 was novel,
and health care workers were heroes for working to
save lives, but in the second wave, patients, relatives,
and health personnel had a fatigue of COVID-19.
(11) We also needed to manage respiratory failure and
the increased oxygen requirement (an almost 5-fold in-
crease) in the hospital, which required technical adjust-
ment of the plants. Use of helmet CPAP increased from
9–10 a day to more than 140 a day.
(12) In my own unit, we decided to have a multidisci-
plinary team, involving the high dependency unit, pul-
monologists and cardiologists (Table 5—Appendix).
We established a cardio-respiratory unit with 44 beds,
where patients would be ventilated but also followed
by a cardiologist directly. The idea was to provide a
very specific way to work for each of our physicians
and nurses, and each physician was involved in the
initial evaluation of the patient, choice of respiratory
support, identification of signs of sepsis or multi-organ
failure, etc.
(13) We have fellows helping each physician: respi-
ratory specialists, cardiologists, nurses, and physio-
therapists—we have 10 physiotherapists working with
us, which was very important for the evaluation of res-
piratory ventilator oxygen support and for early mo-
bilization of the patient. The cardiologists had an im-
portant role in determining appropriate therapy for
hypertension and management of cardiac complica-
tions that are highly significant in COVID. And then
we have consultants specializing in infectious disease,
rheumatology, and intensive care. The intensivist vis-
its twice a day—morning and evening—to evaluate the
patient and discuss the opportunity for intubation or
non-intubation.
(14) We decided to standardize the use of differ-
ent respiratory support measures (high-flow oxygen,
CPAP, NIV, or intubation) according to two parame-
ters: PaO2/FiO2 ratio and respiratory rate (Table 2).
We also standardized the therapeutic approach as soon
as possible, starting from antipyretic drugs to treat-
ment of systemic hypertension using different anti-
hyperintensive drugs (Table 6—Appendix).
(15) For many patients, there was no possibility of oral
nutrition, so we had to use feeding tubes or enteral
feeding. Sedation is an important consideration, partic-
ularly for patients coming from the ICU; we have delir-
ium in many patients after a long period of intubation.
Life support is also very important; we try to prevent
the patient from suffering from respiratory failure and
hypertension, particularly for patients treated with an-
ticoagulation.
(16) Looking into the data, the number of comorbidi-
ties correlates with mortality; the same is true for age—
being older than 65 years is significant in terms of mor-
tality (Figure 2). And we look to the successes and
failures of CPAP treatment in COVID-19. I report here
(Table 3) some of the parameters that are important,
particularly the role of inflammation: CPAP failure is
more frequent when you have a high level of inflam-
mation, high level of risk of thromboembolism, and the
level of FiO2 is also important—if you need a very high
level of FiO2, the risk of CPAP failure is higher.
(17) Another factor is the prone positioning of a pa-
tient treated with CPAP. A prospective cohort study
from our group of intensivists was published in the
Lancet, which observes a positive effect of prone posi-
tioning and contemplates the possibility of long-term
prone positioning.[6] We also examined prone and lat-
eral positioning in a paper published in Chest.[7] For
some patients, it works, and for others, it doesn’t work.
What happens in the first hour is significant in under-
standing whether prone or lateral positioning is work-
ing. This will require more study, but it is clearly im-
portant in understanding the possible role of prone and
lateral positioning for patients in CPAP.
(18) We have patients with different compliance and
different shunt fraction (Figure 3), which led us to
consider the possibility that patients have different re-
sponses and different kinds of acute respiratory dis-
tress syndrome in COVID, which led to a highly contro-
versial paper.[8] Gattinoni and his group of intensivists
in Milan looked into the two possible phenotypes: type
L and type H. Type L is a patient with COVID pneu-
monia with low elastance, low ventilation-to-perfusion
ratio, low lung weight and low lung recruitability. For
these patients, the suggestion is to treat with an in-
crease of FiO2 and non-invasive support. Type H pa-
tients have high elastance, high right-to-left shunt, high
lung weight, and high lung recruitability. For these pa-
tients, the recommendation is to treat the condition as
severe ARDS, with higher PEEP, prone position, and
extracorporeal support. This paper was really contro-
versial, but it is interesting because it led to a huge dis-
cussion about the physiology of ARDS in COVID.
(19) We published a paper last year using
CHA(2)DS(2)-VASc scores for risk of thromboem-
bolism in the lungs, and the higher the score, the higher
the risk of mortality and intubation.[9] The resultant
curve (Figure 4) is not so good, but it’s not so bad. Cer-
tainly this score may be useful to identify patients at
risk. Looking again at the risks factors (Figure 5), age
and comorbidities, especially hypertension, seem to be
significant for mortality.
(20) The cardio-respiratory unit is important because
COVID implies the involvement of both the heart
and the lungs. This is a paper published from an-
other group in Milan and in Bergamo, looking at the
hemodynamic profile of COVID-19.[11] They found
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Table 2. Proposed respiratory support based on the severity of acute respiratory failure.[3]
Acute Respiratory failure Alternative
P/F ratio > 300 and respiratory rate (RR) < 30
Low-flow nasal cannula oxygen or Venturi Mask or Reservoir Mask set with the aim of target SpO2
92–96%
HFNC 40 L/min and FiO2 set with the aim of target SpO2 92–96%
P/F ratio 100–300 and RR < 30 Helmet CPAP with PEEP 5 or 7.5 cmH2O and FiO2 set with the aim of target SpO2 92–96%
P/F ratio < 100 and RR < 30 Helmet CPAP with PEEP 5 or 7.5 cmH2O and FiO2 set with the aim of target SpO2 92–96%
P/F ratio < 100 and RR ≥ 30 and/or respiratory
distress
NIV (Also to consider in case of: CPAP failure, hyper-capnia). NIV starting parameters: PEEP 12–16
cmH20 PS set with the aim of Vt 4–6 ml/kg and FiO2 set with the aim of target SpO2 90–95%
Abbreviations: P/F ratio arterial pO2 divided by the fraction (percent) of inspired oxygen, HFNC High-flow nasal cannula, CPAP Continuous positive airway pressure,
FiO2 fraction (percent) of inspired oxygen, NIV Non-invasive ventilation, PEEP Positive end-expiratory pressure.
Figure 2. Risk factors for mortality—all risk factors were included in the model, clustered by site (n = 2,868). ARB, Angiotensin receptor blocker;
ACEi, Angiotensin converting enzyme inhibitor; BB, Beta-blocker; Di, Diuretic; CA, Ca-antagonist.[4]
Copyright © 2020 Polverino, Stern, Ruocco, Balestro, Bassetti, Candelli, Cirillo, Contoli, Corsico, D’Amico, D’Elia, Falco, Gasparini,
Guerra, Harari, Kraft, Mennella, Papi, Parrella, Pelosi, Poletti, Polverino, Tana, Terribile, Woods, Di Marco, Martinez and the ItaliCO study group.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). No changes were made to this
figure.
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Table 3. [Excerpt] Baseline characteristics, continuous positive airway pressure (CPAP) treatment and outcomes of the study population accord-
ing to CPAP failure or success.[5]
CPAP success CPAP failure p-value
CPAP initiation and treatment
FIO2 % (n=154) 50 (50–60) 60 (50–70) <0.0001
PEEP cmH2O (n=154) 10.4±2.2 11.4±2.4 0.01
Increase of PaO2:FIO2 ratio of at least 20% from oxygen therapy to CPAP 53 (64.6) 33 (48.5) 0.047
Increase of PaO2:FIO2 ratio of at least 30% from oxygen therapy to CPAP 51 (62.2) 27 (39.7) 0.006
Days of CPAP treatment (n=153) 8 (5–14) 4 (3–7) <0.0001
CPAP complications
Pneumothorax 0 (0.0) 1 (1.4) 0.45
Pneumomediastinum 0 (0.0) 2 (2.9) 0.20
Haemodynamic instability 0 (0.0) 9 (12.9) 0.001
Intolerance 10 (11.5) 11 (15.7) 0.44
Ulcer 2 (2.3) 0 (0.0) 0.50
Study outcomes
Weaning from CPAP to oxygen therapy 84 (96.6) 6 (8.6) <0.0001
Days from CPAP initiation to weaning to oxygen therapy (n=87) 7 (4–12) 7 (1–8) 0.31
Intubation 0 (0.0) 34 (48.6) <0.0001
Days from CPAP initiation to intubation (n=34) 3 (2–5)
Mortality in HDU 0 (0.0) 36 (51.4) <0.0001
Days from CPAP initiation to HDU mortality (n=36) 5 (3–10)
Length of hospitalisation (n=138) 18 (14–25.5) 8 (4–22) <0.0001
In-hospital mortality 0 (0.0) 45 (64.3) <0.0001
Figure 3. (A) Distributions of the observations of the compliance values observed in our cohort of patients. (B) Distributions of the observations
of the right-to-left shunt values observed in our cohort of patients.[10]
© 2020 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attri-
bution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). No changes were made to this
figure.
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Figure 4. Receiver Operating Characteristic curves for death and the composite end point of death or invasive ventilation for the predictor of
CHA(2)DS(2)-VASc score (ROC curve analysis was employed to quantify the prognostic power of CHA(2)DS(2)-VASc score for death and also
for the composite end point (death and/or receiving invasive ventilation).[9]
Reprinted from the American Journal of Cardiology, Vol. 137, Gaetano Ruocco, Peter A. McCullough, Kristen M. Tecson, Massimo
Mancone, Gaetano M. De Ferrari, Fabrizio D’Ascenzo, Francesco G. De Rosa, Anita Paggi, Giovanni Forleo, Gioel G. Secco, Gianfranco
Pistis, Silvia Monticone, Marco Vicenzi, Irene Rota, Francesco Blasi, Francesco Pugliese, Francesco Fedele, Alberto Palazzuoli, Mortality Risk
Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection, pages 111–117, Copyright
(2020), with permission from Elsevier.
Figure 5. Forest plot of odds ratios for mortality of individual CHA(2)DS(2)-VASc components (crude OR for death for individual CHA(2)DS(2)-
VASc components: age category, gender, hypertension, diabetes mellitus, ischemic heart disease, stroke, and heart failure).[9]
Reprinted from the American Journal of Cardiology, Vol. 137, Gaetano Ruocco, Peter A. McCullough, Kristen M. Tecson, Massimo
Mancone, Gaetano M. De Ferrari, Fabrizio D’Ascenzo, Francesco G. De Rosa, Anita Paggi, Giovanni Forleo, Gioel G. Secco, Gianfranco
Pistis, Silvia Monticone, Marco Vicenzi, Irene Rota, Francesco Blasi, Francesco Pugliese, Francesco Fedele, Alberto Palazzuoli, Mortality Risk
Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection, pages 111–117, Copyright
(2020), with permission from Elsevier.
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that combined cardiopulmonary alteration leads to a
low pulmonary vascular resistance with blunted hy-
poxic vasoconstriction, which leads to post-capillary
pulmonary hyptertension. So, it’s very important to
take into account the interaction between the lung and
heart. Indeed, we published this paper in the Jour-
nal of the American College of Cardiology, looking at the
echocardiography problems and abnormalities, both
left ventricle wall motion and global dysfunction, but
also right ventricular dysfunction.[12] Almost all of
the patients have some echocardiography abnormal-
ity; myocardial injury is very common in patients with
COVID-19. It’s very important to perform echocardiog-
raphy because echocardiography abnormalities are re-
lated with an odds ratio of almost 4 in terms of mortal-
ity (Figure 6), so it’s very important to have a cardiolo-
gist in your unit looking for abnormalities of heart wall
motion in particular.
(21) These are postmortem findings in patients in
Bergamo (Figure 7), which is the epicenter of the epi-
center in Lombardy.[13] We looked at the coagula-
tion problems, and what we found is that is impor-
tant to look at von-Willebrand factors and ADAMST13
axis.[14] And the increase in the imbalance of this ratio
is important because this is a measure of hypercoagu-
lable state and the risk of microthrombosis in COVID-
19 patients. So, clearly there is something at the level
of endothelium that leads to microthrombosis, which
eventually leads to thromboembolism.
(22) We published a paper in the European Respiratory
Journal, examining the interaction between respiratory
failure and hypertension.[15] What we found is that
most of our patients develop hypertension during the
course of COVID, and the hypertension is related to
the severity of respiratory failure and mortality (Figure
8). Following this paper, we decided to examine the ef-
fect of canrenone and spironolactone as possible treat-
ments for hypertension in these patients. And indeed,
we found that the use of this kind of antihypertensive
drug is important because the there is clinical improve-
ment and reduced chance of mortality in COVID-19 pa-
tients.[16] This is just a few patients; we still need a con-
firmation. We are planning to have a randomized study
on the use of canrenone, and we will see the results, I
hope, in the next few months.
(23) The other problem is inflammation. As I said, af-
ter the first two weeks of March, we decided to start
the use of steroids and anti-inflammatory drugs, using
a combination of methylprednisolone and anakinra,
which is an anti-interleukin 1 drug. This is a retro-
spective analysis of our our results (Figure 9), and you
can see that there is a clear difference using methyl-
prednisolone and anakinra compared to patients in
standard care treatment.[17] It seems, therefore, that
steroids plus or minus anti-interleukin 1 puts the pa-
tient at an advantage compared to an anti-interleukin 6,
because in this case, the activity of anakinra is short, so
you can stop the treatment if there is any compromis-
ing effect on the immunocompetency of your patient.
And it seems to work very well.
(24) As a center for lung transplantation, we suffer
very much from COVID because we have had a reduc-
tion by half in the number of lung transplantations in
our unit; we dropped from almost 40 to less than 20
lung transplantations, and this was related to the lack
of donors. And on the other hand, we have some pa-
tients with COVID-19 after lung transplantation. This
is the first report on the first four cases we recorded in
our unit, and three of them have a very benign short-
term outcome.[18] Unfortunately, one of these patients
died, and the pathological result was that apparently
COVID was the trigger for an allograft dysfunction,
probably inducing rejection in our patient.
(25) For our Genomewide Association Study we put
together our patient population with a Spanish popu-
lation from Barcelona, Madrid, and San Sebastian and
looked into a gene-wide association for severe COVID-
19 respiratory failure.[19] We found two loci that are
important for genetic susceptibility to COVID.1 One is
on chromosome 3, and one was related to the ABO
blood group system. A is the worst outcome—the high-
est risk—B intermediate risk, and O the best outcome.
And listed on the left are other interesting genes that
are mainly related to the response to the virus and ex-
pression of ACE-2 on the cells. So this seems to be re-
lated to the possibility and the response to virus. And
there is clearly an association with different alleles.
(26) So in conclusion, COVID-19 has been a rocket
stimulus for health care in terms of management, new
technology and new therapies. We had to consider how
to deal with the disease and how to manage trying to
standardize our approach to the disease. On the other
hand, we looked to different approaches, in terms of
ventilation, using prone and lateral positioning for pa-
tients with non-invasive ventilation or CPAP. Certainly,
the ideas concerning different phenotypes of COVID-
19 are interesting. We have had a lot of discussion
about this, but certainly it is still important to study the
physiology and pathophysiology of the disease, and
certainly new studies are very welcome. New thera-
pies are important; the use of a control of hypertension
seems to be important. Certainly, anti-inflammatory
drugs are important to control inflammation, knowing
that the so-called cytokine storm seems to be important
in terms of outcome, so controlling inflammation seems
to be critical for our patients. And then we identified
some genes that can be activated and can be means to
identify the different responses to the disease in differ-
1See Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med 2020; 383:1522–1534. Available at: http:
//www.nejm.org/doi/10.1056/NEJMoa2020283.[19]
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Figure 6. Independent predictors of in-hospital death from multivariable logistic-regression analysis.[12]
Reprinted from the Journal of the American College of Cardiology, Vol. 76, Gennaro Giustino, Lori B. Croft, Giulio G. Stefanini, Renato
Bragato, Jeffrey J. Silbiger, Marco Vicenzi, Tatyana Danilov, Nina Kukar, Nada Shaban, Annapoorna Kini, Anton Camaj, Solomon W. Bienstock,
Eman R. Rashed, Karishma Rahman, Connor P. Oates, Samantha Buckley, Lindsay S. Elbaum, Derya Arkonac, Ryan Fiter, Ranbir Singh,
Emily Li, Victor Razuk, Sam E. Robinson, Michael Miller, Benjamin Bier, Valeria Donghi, Marco Pisaniello, Riccardo Mantovani, Giuseppe
Pinto, Irene Rota, Sara Baggio, Mauro Chiarito, Fabio Fazzari, Ignazio Cusmano, Mirko Curzi, Richard Ro, Waqas Malick, Mazullah Kamran,
Roopa Kohli-Seth, Adel M. Bassily-Marcus, Eric Neibart, Gregory Serrao, Gila Perk, Donna Mancini, Vivek Y. Reddy, Sean P. Pinney, George
Dangas, Francesco Blasi, Samin K. Sharma, Roxana Mehran, Gianluigi Condorelli, Gregg W. Stone, Valentin Fuster, Stamatios Lerakis, Martin
E. Goldman, Characterization of myocardial injury in patients with COVID-19, Pages 2043–2055, Copyright (2020), with permission from the
American College of Cardiology Foundation.
Figure 7. Haematoxylin and eosin-stained sections from representative areas of lung parenchyma with diffuse alveolar damage. (A) Exudative
phase of diffuse alveolar damage with hyaline membranes (arrow). (B) Organising microthrombus (arrow).[13]
Reprinted from The Lancet Infectious Diseases, Vol. 20, Luca Carsana, Aurelio Sonzogni, Ahmed Nasr, Roberta Simona Rossi, Alessandro
Pellegrinelli, Pietro Zerbi, Roberto Rech, Riccardo Colombo, Spinello Antinori, Mario Corbellino, Massimo Galli, Emanuele Catena, Antonella
Tosoni, Andrea Gianatti, Manuela Nebuloni, Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre
descriptive study, Pages 1135–1140, Copyright (2020), with permission from Elsevier.
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Figure 8. Box plots of a) oxygen and inspiratory fraction of oxygen ratio, b) alveolar-arterial oxygen gradient, c) mean blood pressure (BP) and
d) plasma potassium levels ([K+]plasma). Statistical significance was obtained through Mann-Whitney U-test comparing best status with worst
status. *: p<0.001. e) Poon’s analysis of PA − aO2 /mean BP: n=137, slope=6.666, R2=0.757; p<0.0001. f) Poon’s analysis of PA − aO2 /mean
BP according to [K+]plasma stratum. In (f) pale blue dots represent the group with [K+]plasma ≤ 3.8mmolL−1 (n=78; slope=6.686, R2=0.774;
p<0.0001) and white dots represent the group with [K+]plasma > 3.8mmolL−1 (n=59; slope=4.491, R2=0.670; p<0.0001). PaO2 : arterial oxygen
tension; FIO2 : inspiratory oxygen fraction; PA − aO2 : alveolar-arterial oxygen tension difference.[15]
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients
Marco Vicenzi, Roberta Di Cosola, Massimiliano Ruscica, Angelo Ratti, Irene Rota, Federica Rota, Valentina Bollati, Stefano Aliberti, Francesco
Blasi. European Respiratory Journal 2020 56: 2001157; DOI: 10.1183/13993003.01157-2020
Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. No changes were made to this
figure.
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ent patients. So, a lot of studies still to go, and we’re still
waiting for new information and new evidence that can
lead us to better management and health care. So, I
want to thank you for your attention.
DR. RAMIREZ
(27) Well, thank you. An excellent overview; a lot
of things to discuss. Let me ask you a couple of
things based on this very interesting presentation. The
concept of hypertension—because I noticed that you
have on a slide that hypertension is the most com-
mon comorbidity that you notice in your group. It’s
interesting; it has been our most common comorbid-
ity here in Louisville. So two questions: firstly, you
have your prior work with pneumonia, pneumococ-
cal pneumonia—how do you connect the prior research
of pneumonia with COVID pneumonia and hyperten-
sion? And then, you mentioned the two types of hy-
pertension; what is the difference between the patient
that arrived with hypertension as a comorbidity (that
is the most common comorbidity) and the patient that
develops hypertension during the hospitalization?
DR. BLASI
(28) Well, I must say that looking into pneumonia,
I never thought of hypertension as a risk factor be-
fore. We know that cardiovascular diseases like my-
ocardial infarction are more probable in pneumonia
than in other diseases coming to the hospital. We are
looking into the possibility that in some way, the in-
fection that is related to the ACE-2 receptor can act on
the aldesterone problems and pathway, so in some way,
there can be an equilibrium between the renin and an-
giotensin pathway and aldosterone levels that can lead
to hypertension. And so, the idea to use canrenone as a
possible drug started from the this kind of pathophys-
iology hypothesis. We are looking into this pathway,
and I think we will have the data in the next few weeks
because we have samples from our patients’ blood, and
we are looking at the levels of angiotensin, renin, and
so on and trying to understand if there is any problem
between the admission and the patient who develops
hypertension during the hospitalization—if it is any
problem in this axis, and we’re trying to understand
the the pathophysiologic basis of hypertension in this
patient.
DR. RAMIREZ
(29) Talking about our prior experience with pneumo-
nia, again, as you alluded, hypertension was never too
much of a comorbidity. But in other forms of pneu-
monia, probably one of the primary causes was smok-
ing and COPD. But I notice that in your data, COPD
is almost non-existent. And again, I see the same
in our data here in Louisville. Why is it that COPD
and smoking—all these things that cause chronic lung
disease—don’t seem to play such a critical role here.
We have it with pneumococcus or with other with other
forms of pneumonia; what do you make of it here?
DR. BLASI
(30) There’s no good explanation. One possibility is
that steroids could be involved. If you consider asth-
matic patients, you have some effects where they have
a reduction, but severe asthmatics are not at a low inci-
dence of COVID. Maybe it’s related to biologicals or to
the kind of inflammation and the use of steroids. The
number of patients coming to the hospital with the co-
morbidity of COPD is not as high as expected, but if a
patient with COPD comes to the hospital with COVID,
the outcome may be worse than for other patients. I
don’t have a very good explanation for this. We are
seeing the same for our patients with bronchiectasis;
we don’t have a lot of patients with bronchiectasis or
cystic fibrosis come into the hospital with COVID, but
this may be related to the fact that these patients are
used to being very cautious. They use masks, they stay
at home, avoiding contact with other people, so it’s eas-
ier to explain why bronchiectasis and cystic fibrosis pa-
tients have a lower incidence of COVID than expected,
but for COPD, it is very difficult to understand why. It
may relate to the use of steroids, but I don’t know what
the explanation is.
DR. RAMIREZ
(31) Let me ask you another question about the patho-
physiology. Do you think that that that COVID pneu-
monia or the SARS-CoV-2 will get into the oropharynx
via aspiration, inhalation, pneumonia with hematoge-
nous spread—some people suggest even the possibility
of some form of auto-immune disease—what is run-
ning through your mind when you discuss with your
group, what would be the pathophysiology, how is
it that these patients develop COVID pneumonia; are
there really two types of ARDS—one type that pro-
gresses into another one—what is your your thought
process regarding this at this moment?
DR. BLASI
(32) Well, looking to the receptors for the virus—along
the airways you have receptors everywhere. Usually
inhalation is the means of passing from the mouth to
the lung. What happened then, I think, is a matter of in-
dividual response in terms of inflammation, the num-
ber of receptors, maybe related to the viral loads. It
is not very clear what happened. What we see is that
when the patient comes to the hospital, 7–10 days after
the onset of symptoms, usually the virus is no longer
the main problem. Rather, inflammation is the main
problem.
(33) What we saw in March last year is that when we
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started to use steroids, our patients’ outcomes changed.
We started steroids because our pulmonologists looked
into the lungs and noticed their ground glass appear-
ance, and we theorized that inflammation was signifi-
cant, so we started to use steroids, despite the fact that
at the time, the WHO said not to use steroids, because
it’s a viral infection. I think that the pathophysiology
is probably related to the number of receptors, maybe
the genetics because we found that there are differences
in terms of severity according to different gene expres-
sions, and the level of inflammation. We know that
in pneumonia, inflammation is significant; your group
has published a lot of papers on this. It’s not just the
question of bacterial versus viral infection. So, prob-
ably, there is a different response in different subjects,
and so I think it’s a very complex problem.
DR. RAMIREZ
(34) But definitely, you’ve seen decreased mortality
with the use of steroids, usually?
DR. BLASI
(35) Absolutely. We published a paper some years
ago with Marco Confalonieri in the Blue Journal, and
we used the same approach with steroids.[20] In some
patients, we also use a pulse of steroids to reduce
inflammation—so, using a very high dose for three
days, and then decreasing, like we do for rejection in
lung transplantation. And this is a decision patient by
patient; if there is no response, or if there is an increase
in the ground glass appearance, we start with the high
dose. We know very well that this approach is risky
in many ways because when you use a high dose of
steroids, there are many potential problems. Now we
use dexamethasone for many patients because we have
a protocol for it, but I think that in about half of our pa-
tients, we move from dexamethasone to methylpred-
nisolone on high dose, and we get a response.
DR. RAMIREZ
(36) You have experience with lung transplantation
during the pandemic; what criteria would you use to
determine that a patient may be a candidate for lung
transplantation?
DR. BLASI
(37) Well, we transplanted two patients. One was a
young patient, 18 years old, who was intubated in an-
other hospital. The situation was bad: there was no
possibility of improvement, the lung was completely
destroyed, so the hospital asked us to consider the
possibility of lung transplantation. We had a multi-
disciplinary discussion—a couple of days’ discussion;
we analyzed everything because of the presence of
COVID. We had to induce immunosuppression, so we
decided to make a plasma treatment, and then we de-
cided to try lung transplantation, and this guy is still
alive and in good condition; he was transplanted in
April of last year, and he’s still doing very well. The
other was a 49-year-old guy, the same situation in our
hospital, but in this case, the transplantation was a dis-
aster. After the lung transplantation he was intubated
again—it was not possible to avoid intubation—and he
died after two months of intubation. So, our experience
is not so good. I have seen some reports around the
world, for instance in China, four people were trans-
planted, three of them went well, and one died. I think
we don’t really have enough experience to say any-
thing definitive. For us, it was really an emergency de-
cision; it wasn’t based on solid criteria.
DR. RAMIREZ
(38) I understand. Then this 18-year-old was not hav-
ing multi-organ failure; it was mostly concentrated in
the lung?
DR. BLASI
(39) Yes, his heart, kidney, and liver were all working,
but the lung was completely destroyed. So we decided
that there was no major problem in terms of lung trans-
plantation, and our surgeon and intensivist decided to
go for it, and it was a good decision. The other patient
had kidney failure, and this was the main problem, I
think, because he was on dialysis, and it was not a good
idea to transplant him.
DR. RAMIREZ
(40) This has been a lot of lessons learned, and I like
your concept that since this is a new disease, there is no
evidence base, so experience is critical, along with the
multidisciplinary approach and the standardization. In
the last couple of minutes, I would like to ask: looking
at 2021, you eluded to the concept of what would be
the “COVID fatigue.” How do you see this, and what
is the way to move forward? Because as these new
waves keep coming all over the world, I can see that
the COVID fatigue is going to be a universal problem.
DR. BLASI
(41) In the first wave, when we opened the unit, we all
felt like heroes working against the virus, and we were
a very strong team working together, nurses, physio-
therapists, cardiologists, respiratory disease. Then we
had a couple of months working as pulmonologists,
rather than COVID specialists, and then we had to re-
open the unit, and it was extremely difficult, because
of the idea of another year with COVID working on
this kind of patient, seeing people dying with a re-
ally high frequency (around 20%). So we started with
psychological support; I have three or four of my co-
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workers going regularly to the psychologist, and I meet
with each of them because I think that having an ex-
change of experience is important. And now we are
meeting all together every week, trying to restart our
souls, as it were. It’s also related to the fact that in the
first wave, the Italian population saw physicians and
nurses as heroes. Now, they are starting to say, “well,
you didn’t do exactly what you had to do.” So I asked
my lawyer to look into this [laughs]. So, psychological
support is very important, particularly in the second
wave because the fatigue is definitely there.
DR. RAMIREZ
(42) This is very good experience and very good ad-
vice. Before I let you go, I need to ask whether you
think the vaccines are going to fix any of these prob-
lems because I can see that the vaccine will help us to
not get COVID, but as you say, going to the unit and
having 20% mortality and being separated from the pa-
tient with all this protective equipment—I don’t think
the vaccine is going to resolve this. How do you see
the vaccine? How is the vaccine going in your area, in
Milan, and how do you see the vaccine for this coming
year?
DR. BLASI
(43) Well, I think it will take about one year to vacci-
nate the Italian population, considering that we plan
to vaccinate all people over 16—that means about 45
million people, which is not an easy task. I was one
of the first in December to be vaccinated, and I’m ex-
pecting the second dose in a couple of days. I think the
key point is that the vaccines will reduce the pressure
on the hospital a little, because if we can prevent the
most severe cases in the elderly, it would be a great help
in controlling the situation. Our problem right now is
that our emergency room is full of people with COVID,
and we don’t have time to care for the other (COVID-
negative) patients with myocardial infarction, COPD or
asthma exacerbation. So I think that what we expect
from the vaccine is some reduction in pressure, not a
complete solution to the problem. I think that this dis-
ease will become endemic in some way, like Legionella,
for example. But the important thing is to reduce the
pressure on the health system, and there are logistical
problems because vaccinating so many people is very
difficult. Our system is not ready because this is the
first time we have had to vaccinate 45 million people,
and it’s clearly weird to think about how to deal with
this. We started with health workers, but that’s very
easy because they are in the hospital; each hospital is
vaccinating its own staff. But then we have to go out-
side into the community and try to vaccinate 100,000
people a week or more.
DR. RAMIREZ
(44) Well, let me say that this was a great conversa-
tion. Thank you for accepting our invitation. As we
discussed, this is not the same as our face-to-face inter-
national meetings, but let’s hope that at least the vacci-
nation is going to resolve this issue and we can be face-
to-face in a meeting in a couple of months. But yes, a
lot of challenges, a lot of things to learn. Thank you for
your time, and I will keep in contact.
DR. BLASI
(45) Thank you very much; it was a really great time
for me.
Received: February 9, 2021
Accepted: February 23, 2021
Published: March 5, 2021
Copyright: © 2021 The author(s). This original article is
brought to you for free and open access by ThinkIR: The Uni-
versity of Louisville’s Institutional Repository. For more infor-
mation, please contact thinkir@louisville.edu. This article is
distributed under the terms of the Creative Commons Attribu-
tion 4.0 International License (CC BY 4.0), which permits un-
restricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding Source: The author(s) received no specific funding
for this study.
Conflict of Interest: All authors declared no conflict of inter-
est in relation to the main objective of this work.
References
1. Grasselli G, Zangrillo A, Zanella A, et al. Baseline charac-
teristics and outcomes of 1591 patients infected with SARS-
CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA
2020; 323(16): 1574–81. doi: 10.1001/jama.2020.5394.
PMID: 32250385.
2. Carenzo L, Costantini E, Greco M, et al. Hospital surge
capacity in a tertiary emergency referral centre during the
COVID-19 outbreak in Italy. Anaesthesia 2020; 75(7): 928–
34. doi: 10.1111/anae.15072. PMID: 32246838.
3. Aliberti S, Amati F, Pappalettera M, et al. COVID-19 mul-
tidisciplinary high dependency unit: the Milan model. Respir
Res 2020; 21(1): 260. doi: 10.1186/s12931-020-01516-8.
PMID: 33036610.
4. Polverino F, Stern DA, Ruocco G, et al. Comorbidities,
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/3 14
ULJRI IRIS COVID Research Conversations: Podcast 1 with Dr. Francesco Blasi
Cardiovascular Therapies, and COVID-19 Mortality: A Na-
tionwide, Italian Observational Study (ItaliCO). Front Cardio-
vasc Med 2020; 7: 585866. doi: 10.3389/fcvm.2020.585866.
PMID: 33195473.
5. Aliberti S, Radovanovic D, Billi F, et al. Helmet CPAP
treatment in patients with COVID-19 pneumonia: a multi-
centre cohort study. European Respiratory Journal 2020;
56(4): 2001935. doi: 10.1183/13993003.01935-2020. PMID:
32747395.
6. Coppo A, Bellani G, Winterton D, et al. Feasibility and
physiological effects of prone positioning in non-intubated pa-
tients with acute respiratory failure due to COVID-19 (PRON-
COVID): a prospective cohort study. Lancet Respir Med
2020; 8(8): 765–74. doi: 10.1016/s2213-2600(20)30268-x.
PMID: 32569585.
7. Retucci M, Aliberti S, Ceruti C, et al. Prone and
lateral positioning in spontaneously breathing patients
with COVID-19 pneumonia undergoing noninvasive helmet
CPAP treatment. Chest 2020; 158(6): 2431–5. doi:
10.1016/j.chest.2020.07.006. PMID: 32679237.
8. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneu-
monia: different respiratory treatments for different pheno-
types? Intensive Care Med 2020; 46(6): 1099–102. doi:
10.1007/s00134-020-06033-2. PMID: 32291463.
9. Ruocco G, McCullough PA, Tecson KM, et al. Mortality risk
assessment using CHA(2)DS(2)-VASc scores in patients hos-
pitalized with Coronavirus Disease 2019 infection. Am J Car-
diol 2020; 137: 111–7. doi: 10.1016/j.amjcard.2020.09.029.
PMID: 32991860.
10. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S,
Chiumello D. COVID-19 does not lead to a “typical” acute res-
piratory distress syndrome. Am J Respir Crit Care Med 2020;
201:1299–1300. doi: 10.1164/rccm.202003-0817LE. PMID:
32228035.
11. Caravita S, Baratto C, Di Marco F, et al. Haemodynamic
characteristics of COVID-19 patients with acute respiratory
distress syndrome requiring mechanical ventilation. An inva-
sive assessment using right heart catheterization. Eur J Heart
Fail 2020; 22(12): 2228–37. doi: 10.1002/ejhf.2058. PMID:
33200458.
12. Giustino G, Croft LB, Stefanini GG, et al. Char-
acterization of myocardial injury in patients with COVID-
19. J Am Coll Cardiol 2020; 76(18):2043–55. doi:
10.1016/j.jacc.2020.08.069. PMID: 33121710.
13. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-
mortem findings in a series of COVID-19 cases from northern
Italy: a two-centre descriptive study. Lancet Infect Dis 2020;
20(10):1135–1140. doi: 10.1016/S1473-3099(20)30434-5.
PMID: 32526193.
14. Mancini I, Baronciani L, Artoni A, et al. The ADAMTS13-
von Willebrand factor axis in COVID-19 patients. Jour-
nal of Thromb Haemost 2021; 19(2): 513–21. doi:
10.1111/jth.15191. PMID: 33230904.
15. Vicenzi M, Di Cosola R, Ruscica M, et al. The liaison be-
tween respiratory failure and high blood pressure: Evidence
from COVID-19 patients. Eur Respir J 2020; 56(1):2001157.
doi: 10.1183/13993003.01157-2020. PMID: 32430432.
16. Vicenzi M, Ruscica M, Iodice S, et al. The efficacy
of the mineralcorticoid receptor antagonist canrenone in
COVID-19 patients. J Clin Med 2020; 9(9): 2943. doi:
10.3390/jcm9092943. PMID: 32933039.
17. Bozzi G, Mangioni D, Minoia F, et al. Anakinra combined
with methylprednisolone in patients with severe COVID-19
pneumonia and hyperinflammation: An observational cohort
study. J Allergy Clin Immunol 2021; 147(2): 561–6.e4. doi:
10.1016/j.jaci.2020.11.006. PMID: 33220354.
18. Morlacchi LC, Rossetti V, Gigli L, et al. COVID-19 in lung
transplant recipients: A case series from Milan, Italy. Transpl
Infect Dis 2020; 22(6): e13356. doi: 10.1111/tid.13356.
PMID: 32510771.
19. The Severe COVID-19 GWAS Group. Genomewide as-
sociation study of severe Covid-19 with respiratory failure.
N Engl J Med 2020; 383(16): 1522–34. doi: 10.1056/NEJ-
Moa2020283. PMID: 32558485.
20. Confalonieri M, Urbino R, Potena A, et al. Hydrocor-
tisone infusion for severe community-acquired pneumonia:
A preliminary randomized study. Am J Respir Crit Care
Med 2005; 171(3):242–8. doi: 10.1164/rccm.200406-808OC.
PMID: 15557131.
ULJRI | https://ir.library.louisville.edu/jri/vol5/iss1/3 15
ULJRI IRIS COVID Research Conversations: Podcast 1 with Dr. Francesco Blasi
Appendix: Large Tables
Table 4. Demographic and clinical characteristics of patients in the first 24 hours of ICU admission for COVID-19 in Lombardy, Italy.[1]
Patients by age, y, No. (%)
All 0–20 21–40 41–50 51–60 61–70 71–80 81–90 91–100
No. (%) 1591 (100) 4 (<1) 56 (4) 143 (9) 417 (27) 598 (38) 341 (21) 21 (1) 1 (<1)
Age, medium (IQR), y 63 (56-70) 16 (14-19) 34 (31-38) 47 (44-49) 56 (54-59) 65 (63-68) 74 (72-76) 83 (81-84) 91
Males 1304 (82) 3 (75) 44 (79) 119 (83) 355 (83) 484 (81) 279 (82) 19 (90) 1 (100)
Females 287 (18) 1 (25) 12 (21) 24 (17) 72 (17) 114 (19) 62 (18) 2 (10) 0
Comorbidities, No. with data 1043 3 35 82 273 380 253 1 1
None 334 (32) 0 23 (66) 50 (61) 107 (39) 107 (28) 47 (19) 0 0
Hypertension 509 (49) 0 4 (11) 21 (26) 121 (44) 195 (51) 156 (62) 12 (75) 0
Cardiovascular diseasea 223 (21) 0 1 (3) 4 (5) 43 (16) 87 (23) 81 (32) 6 (38) 1 (100)
Hypercholesterolemia 188 (18) 0 1 (3) 2 (2) 30 (11) 92 (24) 59 (23) 5 (31) 0
Diabetes, type 2 180 (17) 0 1 (3) 4 (5) 40 (15) 86 (23) 46 (18) 3 (19) 0
Malignancyb 81 (8) 0 0 2 (2) 10 (4) 33 (9) 33 (13) 3 (19) 0
COPD 42 (4) 0 1 (3) 0 8 (3) 13 (3) 5 (2) 1 (6) 0
Chronic kidney disease 36 (3) 0 0 2 (2) 10 (4) 17 (4) 7 (3) 0 0
Chronic liver disease 28 (3) 0 0 2 (2) 8 (3) 13 (3) 5 (2) 0 0
Otherc 205 (20) 3 (100) 6 (17) 10 (12) 49 (18) 77 (20) 55 (22) 5 (31) 0
Respiratory support, No. 1300 2 46 108 351 487 287 18 1
Invasive mechanical ventilation 1150 (88) 2 (100) 37 (80) 87 (81) 315 (90) 449 (92) 246 (86) 14 (78) 0
Noninvasive ventilation 137 (11) 0 8 (17) 16 (15) 33 (9) 36 (7) 39 (14) 4 (22) 1 (100)
Oxygen mask 13 (1) 0 1 (2) 5 (5) 3 (1) 2 (¡1) 2 (1) 0 0
PEEP, cm H2O
No. 1017 2 33 81 278 377 234 11 1
Median (IQR) 14 (12-16) 9.5 (5-14) 14 (10-15) 14 (12-15) 14 (12-15) 14 (12-16) 14 (12-15) 12 (8-15) 10
FiO2, %
No. 999 2 31 81 270 375 228 11 1
Median (IQR) 70 (50-80) 40 (30-50) 60 (50-70) 60 (50-80) 65 (50-80) 70 (55-80) 70 (50-80) 60 (50-90) 60
PaO2/FiO2 ratio





























ECMO, No./total (%) 5/498 (1) NA 0/15 0/42 2/149 (1) 3/193 (2) 0/95 0/4 NA
a Cardiovascular disease includes cardiomyopathy and heart failure. b Malignancy includes active neoplasia and neoplasia in remission. c Other includes anemia,
asthma, inflammatory bowel disease, epilepsy, chronic respiratory insufficiency, endocrine disorders, connective tissue diseases, neurologic disorders, chronic pan-
creatitis, immunocompromise, and organ transplant. Abbreviations: COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation;
FiO2, fraction of inspired oxygen; ICU, intensive care unit; IQR, interquartile range; NA, not applicable; PaO2, arterial partial pressure of oxygen; PEEP, positive-end
expiratory pressure.
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Table 5. Healthcare professionals involved in the multidisciplinary team.[3]
Respiratory physician Initial evaluation of patient
Choice of respiratory support
Evaluation and placement of central venous catheter and/or arterial catheter
Identify signs of sepsis or multi-organ failure
Setting of sedative therapy, nutritional therapy, anti-thrombotic prophylaxis, hydration, antiviral and antibiotic therapy
Fellow Initial evaluation of patient
Placement of arterial catheter
Blood and microbiological tests request
Arterial blood gas test
Pneumonia follow-up with lung ultrasound
Nurse Preparation of medical devices to support respiratory insufficiency
EKG
Placement of peripheral venous catheter
Placement of bladder catheter
Collection of vital parameters
Therapies administration
Respiratory physiotherapist Evaluation with respiratory physician of ventilator/oxygen support
Early mobilization
Cardiologist Evaluation and placement of central venous catheter and/or arterial catheter
Identification and management of cardiac complications
Anti-hypertensive therapy
Inotropic support
Infectious disease specialist Identification of patients candidate to anti-viral or anti-inflammatory therapy
Choice of antiviral drugs
Choice of antibiotic therapy
Identification and treatment of sepsis
Super-infection identification and management
Rheumatologist Identification of patients candidate to the anti-inflammatory and specific anti-cytokine treatment
Definition of a tailored anti-inflammatory strategy according to the patient characteristics
Intensivist Multidisciplinary discussion to early identify patients candidate to intensive care management
DNI/DNR status
Abbreviations: EKG Electrocardiogram, DNI Do not intubate, DNR Do not resuscitate.
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Table 6. Other therapies for patients with COVID-19 disease.[3]
Antipyretic
Paracetamol 1 g intravenous/orally every 8 h (with the goal to keep fever under control in patients with respiratory insufficiency) for all
patients with body temperature > 37°C.
Alternative:Diclofenac 75 mg intravenous in 24 h.
Metamizole 500 mg intravenous every 8 h.
Systemic hypertension
treatment
Patients with systemic hypertension already on medication: antihypertensive therapy should be continued regardless of pharmaco-
logic (ACE-inhibitor, sartan, beta-blocker). Diuretics should be discontinued to avoid hypovolemic status.
Patients that develop systemic hypertension during the hospitalization: treatment options include potassium-spring diuretics (spirono-
lactone 50 mg x 2/die or potassium canreonate intravenous with a minimum dose of 100 mg x 2/die) associated with ACE-inhibitors
or sartans.
Hydration Hydration should be considered in all patients (especially patients with fever).
Before start of treatment with CPAP or NIV hydration should be provided in patients with signs of hypovolemia.
Nutrition
In patients that are able to eat in HFNC or nasal cannulas: self-sufficient oral feeding
CPAP or NIV-dependent: nasal feeding tube should be placed to provide enteral feeding (e.g.: isosource protein 25 Kcal/kg)
In selected cases parenteral feeding (after positioning of central arterial access):1. BMI ≥ 20 provide at least 1080 kcal (speed:1,5
ml/kg/h)
2. BMI < 20 provide at least 1540 kcal (speed:1,5 ml/kg/h)
Sedation Anxious state: Alprazolam (starting dose 0,25 mg x 2/die orally)
Psychomotor agitation, attempt to remove medical devices, tachypnoea: morphine bolus (2,5 mg i.v./s.c., max every 6 h) ± Alprazolam
(starting dose 0,25 mg x 2/die). At least 2 h between administration of alprazolam and morphine.
End of life support Starting dose: syringe pump with morphine 10 mg + midazolam 5 mg + haloperidol 5 mg + metoclopramide 10 mg
Dose should be modified according to clinical condition of the patient






Beta-blockers and others essential cardiological therapies
Insulin in diabetic patients (oral antihyperglycemic should be discontinued in case of P/F ratio < 300 or acute kidney injury)
Corticosteroid therapy (decalage should be encouraged based on clinical condition of underlying condition)
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